Hydrazono-malonitriles

Details Hydrazono-malonitriles Hydrazono-malonitriles

2006-08-02

2009-06-09

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S247000, C514S248000, C514S249000, C514S252020, C514S252030, C514S252040, C514S252050, C206S570000, C544S224000, C544S238000

Reexamination Certificate

active

07544684

ABSTRACT:
Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′and R4have the meanings given in Claim1act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

REFERENCES:
patent: 98 06704 (1998-02-01), None
patent: 99 65880 (1999-12-01), None
patent: 00 26201 (2000-05-01), None
patent: 01 04099 (2001-01-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1” John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Paharmaceutices, 3ed.” Marcel Dekker, New York, 1996, pp. 451 and 596.
Hungarian Abstract P0001760 (May 28, 2001).

Affiliated with

Also associated with

Rating

Hydrazono-malonitriles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrazono-malonitriles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazono-malonitriles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4086729